| Revenue growth | 19.1% YoY Q4 growth to 920cr; FY26 revenue up 13.8%. |
|---|---|
| Margins | EBITDA margins expanded 593 bps to 21.7% in Q4. |
| Demand visibility | Strong traction in animal health and complex human health generics. |
| Management confidence | Extremely high following successful integration and strongest quarter in company history. |
Growth
Strong 19% Q4 revenue growth driven by animal health and US human health formulations.
Outlook
Targeting 1000cr EBITDA within 2-3 years at 15% annual growth rate.
Risks
High receivables in specific geographies like Turkey and sensitivity to solvent price volatility.
Earnings Call filed with BSE, NSE: VIYASH. Summary written with AI assistance from the document.
Viyash Scientific Ltd: key numbers
- Share price
- ₹241.70
- Market cap
- ₹10,674 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 62.4×Sector 47.4×
- Promoter holding
- 61.31%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Viyash Scientific Ltd
All →Viyash Scientific Employee Stock Options
Viyash Scientific allotted 1,107,309 ESOP shares at exercise prices of ₹86 and ₹101. Paid-up capital rose to ₹88.33 Crore post-allotment.
Viyash Scientific Merger & Restructuring
Viyash Scientific Limited announced receipt of Italian regulatory approval for its subsidiary Alivira Animal Health's acquisition of BioForLife Italia S.r.l. The transaction completion timeline is extended.
Viyash Scientific Acquisition
Viyash Scientific Limited received Italian regulatory approval for its proposed 100% acquisition of BioForLife Italia S.r.l., with the completion timeline now extended by two months.
Viyash Scientific Employee Stock Options
Viyash Scientific Limited allotted 6,12,773 equity shares following the exercise of options under its ESOP 2020 and 2026 schemes. The company's paid-up capital increased to Rs. 88.10 Crore.
Viyash Scientific Promoter Selling
Promoters CA Harbor Investments and CA Hull Investments sold a combined 5.03 crore equity shares of Viyash Scientific Limited through open market transactions.
Viyash Scientific Investor Presentation: Key Takeaways
Viyash Scientific delivered strong Q1 FY27 results with 19.5% revenue growth and significant margin expansion. Integration is complete, and the company is now virtually debt-free, pivoting toward oncology and companion animal health.
- Call
- Guides 18% growth